BioSpace

Estuary sails into kidney disease space with $103M for gene therapies

Estuary Biotherapeutics is seeking to address the root cause of autosomal dominant polycystic kidney disease with two gene therapy programs based on science from Yale.

By BioSpace

1 min read
Estuary sails into kidney disease space with $103M for gene therapies
AI-generated illustration

Got news to share with the events industry?

Submit a press release or story tip and reach thousands of event professionals.

Get in touch→

More in Health Tech

Related Insights